Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Effects on Synaptic Plasticity in Depression
NCT04091971Phase 4Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Oct 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ketamine in major depressive disorder (MDD), sponsored by New York State Psychiatric Institute. Started Oct 2020; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04091971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04091971.